MSCLF and MSCL Related Headlines
Go Back- Satellos begins phase 2 trial of SAT-3247 for duchenne muscular dystrophy
- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos launches public offering, files for NASDAQ listing
- Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
- Satellos names Antoinette Paone as chief development officer
- Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
- Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
- Satellos gets FDA clearance for pediatric Duchenne study
- Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in December Investor Conferences
- Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
- Satellos appoints Mark Nawacki to board, advances DMD drug trials
- Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
- Satellos to Participate in November Investor Conferences
- Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
- Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
- Satellos to present SAT-3247 clinical data at muscle society congress
- Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
- Satellos files for Phase 2 trial of SAT-3247 in children with Duchenne
- Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
- Satellos to Participate in Four September Institutional and Retail Investor Conferences
- Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
- Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
- Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
- Satellos Bioscience (MSCL) announces AGM results
- Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
- Satellos Bioscience Shareholders Elect Two New Board Members
- Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
MSCLF and MSCL Related Press Releases
Go Back- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
- Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
- Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
- Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
- Satellos to Participate in December Investor Conferences
- Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
- Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
- Satellos to Participate in November Investor Conferences
- Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
- Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
- Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
- Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
- Satellos to Participate in Four September Institutional and Retail Investor Conferences
- Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
- Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
- Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
- Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
- Satellos Bioscience Shareholders Elect Two New Board Members
- Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
